Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial

RCT (n-280) found that over 16 weeks, lebrikizumab, a monoclonal antibody targeting IL-13, was linked to significant improvement in Eczema Area and Severity Index (-62.3%, -69.2% and -72.1% for 125mg 4-weekly, 250mg 4-weekly or 250mg 2-weekly, respectively).vs placebo (-41.1%)


JAMA Dermatology